{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:38:40Z","timestamp":1794357520355,"version":"4.9.0"},"update-to":[{"DOI":"10.1002\/14651858.cd000544.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000}}],"reference-count":189,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000544.pub5","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T17:27:47Z","timestamp":1599758867000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis"],"prefix":"10.1002","volume":"2020","author":[{"given":"Alistair","family":"Murray","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine & Dentistry; University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran M","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E","family":"Parker","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London Canada"},{"name":"Department of Medicine; University of Western Ontario; London Canada"},{"name":"Department of Epidemiology and Biostatistics; University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"10.1002\/14651858.CD000544.pub5-BIB0001|cit1","first-page":"170","article-title":"5-aminosalicylic acid (5-ASA) versus salazopirin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission","author":"Andreoli","year":"1987","journal-title":"Clinical Controversies in Inflammatory Bowel Disease"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00004836-199512000-00007","article-title":"Coated oral 50 aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis","volume":"21","author":"Ardizzone","year":"1995","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0003|cit3","first-page":"A1467","article-title":"Comparison of mesalazine with sulphasalazine in prophylactic treatment of ulcerative colitis","volume":"30","author":"Bianchi Porro","year":"1989","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2036.1999.00473.x","article-title":"Is maintenance therapy always necessary for patients with ulcerative colitis?","volume":"13","author":"Ardizzone","year":"1999","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/0140-6736(92)91601-4","article-title":"Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis","volume":"339","author":"Courtney","year":"1992","journal-title":"Lancet"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD000544.pub5-BIB0006|cit6","first-page":"A165","article-title":"Prospective randomized trial of mesalazine versus olsalazine in ulcerative colitis","volume":"98","author":"Courtney","year":"1990","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/ajg.2012.103","article-title":"Once-daily MMX\u00ae mesalamine for endoscopic maintenance of remission of ulcerative colitis","volume":"107","author":"D'Haens","year":"2012","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"A454","DOI":"10.1016\/S0016-5085(08)82250-0","article-title":"Prospective randomized open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with UC in remission","volume":"120","author":"Deventer","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/bmj.287.6384.23","article-title":"Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth","volume":"287","author":"Dew","year":"1983","journal-title":"British Medical Journal"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD000544.pub5-BIB0010|cit10","first-page":"A983","article-title":"Maintenance of remission in ulcerative colitis with an oral preparation of 5-aminosalicylic acid in high doses","volume":"24","author":"Dew","year":"1983","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD000544.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.crohns.2011.10.006","article-title":"Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing","volume":"6","author":"Bokemeyer","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/S1873-9946(13)60381-5","article-title":"Symptom resolution and clinical remission in patients with mild-to-moderate ulcerative colitis: analysis of the PODIUM trial","volume":"7","author":"Dignass","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Dignass A Bokemeyer B Stijnen T Klugmann T Oudkerk M Veerman H Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial Canadian Journal of Gastroenterology 2009","DOI":"10.1016\/S0016-5085(09)63156-5"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0014|cit14","first-page":"S73","article-title":"Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis","volume":"23","author":"Dignass","year":"2009","journal-title":"Canadian Journal of Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0015|cit15","first-page":"A502","article-title":"Pentasa (mesalazine) once or twice daily for the management of maintenance of remission of ulcerative colitis: demographic and baseline data of a 12 month single blind randomised controlled trial","volume":"132","author":"Dignass","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0016|cit16","unstructured":"Dignass A Vermeire S Adamek H Befrits R Bokemeyer B B\u00f6rner N Improved remission rates from once- versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial UEGW \u2013 Abstract Database 2007 OP G-378"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.cgh.2009.04.004","article-title":"Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis","volume":"7","author":"Dignass","year":"2009","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0018|cit18","first-page":"A494","article-title":"Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial","volume":"134","author":"Dignass","year":"2008","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0019|cit19","first-page":"A495","article-title":"Treatment acceptability in a randomised controlled trial of once-daily or twice-daily mesalazine (Pentasa) for the maintenance of remission in ulcerative colitis","volume":"134","author":"Dignass","year":"2008","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0020|cit20","first-page":"A685","article-title":"Impact of once-daily versus twice-daily mesalazine (Pentasa) on relief of rectal bleeding and stool frequency: results from a multinational randomised controlled trial","volume":"136","author":"Dignass","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0021|cit21","first-page":"S520","article-title":"The PODIUM trial of once-daily versus twice-daily mesalazine dosing in ulcerative colitis: maintenance of mucosal healing","volume":"1","author":"Dignass","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0022|cit22","first-page":"S522","article-title":"Efficacy of once-daily versus twice-daily mesalazine (Pentasa): sub-analysis of the left-sided colitis population in the randomised PODIUM trial","volume":"1","author":"Vermeire","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0023|cit23","first-page":"A701","article-title":"Relapse prevention of ulcerative colitis: double-blind comparison of 1.5 gram versus 3 gram oral mesalazine (Pentasa)","volume":"104","author":"Fockens","year":"1993","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD000544.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/00042737-199511000-00003","article-title":"Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group","volume":"7","author":"Fockens","year":"1995","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2036.1992.tb00561.x","article-title":"Improved maintenance of remission in ulcerative colitis by balsalazide 4 g\/day compared with 2 g\/day","volume":"6","author":"Giaffer","year":"1992","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD000544.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MCG.0000000000000414","article-title":"Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis","volume":"50","author":"Gordon","year":"2016","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2036.1992.tb00578.x","article-title":"Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months","volume":"6","author":"Green","year":"1992","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD000544.pub5-BIB0028|cit28","first-page":"A631","article-title":"A three-year prospective study of the maintenance of remission of ulcerative colitis by a new 5-ASA releasing agent, balsalazide","volume":"102","author":"Green","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1046\/j.1365-2036.1998.00427.x","article-title":"Maintenance of remission of ulcerative colitis: a comparison between balsalzide 3 g daily and mesalazine 1.2 g daily over 12 months","volume":"12","author":"Green","year":"1998","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0030|cit30","first-page":"A696","article-title":"Maintenance of remission of ulcerative colitis by mesalamine (Asacol) versus placebo","volume":"106","author":"Hanauer","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7326\/0003-4819-124-2-199601150-00003","article-title":"An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial","volume":"124","author":"Hanauer","year":"1996","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1053\/gast.1997.v112.pm9041232","article-title":"A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis","volume":"112","author":"Hawkey","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0033|cit33","first-page":"A37","article-title":"Once daily asacol in maintenance therapy for ulcerative colitis: a one-year singe-blind randomised trial","volume":"60","author":"Hawthorne","year":"2011","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0016-5085(11)60265-5","article-title":"Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial","volume":"140","author":"Hawthorne","year":"2011","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD000544.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/ibd.21938","article-title":"One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis","volume":"18","author":"Hawthorne","year":"2012","journal-title":"Inflammatory Bowel Disease"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0036|cit36","first-page":"A1447","article-title":"Comparative trial of olsalazine and sulfasalazine for the maintenance treatment of ulcerative colitis (UC)","volume":"92","author":"Ireland","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/gut.29.6.835","article-title":"Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis","volume":"29","author":"Ireland","year":"1988","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/00365528809101547","article-title":"Controlled trial comparing olsalazine and sulfasalazine for maintenance treatment of ulcerative colitis","volume":"148","author":"Jewell","year":"1988","journal-title":"Scandinavian Journal of Gastroenterology. Supplement"},{"issue":"9","key":"10.1002\/14651858.CD000544.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/ibd.21194","article-title":"Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study","volume":"16","author":"Ito","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0040|cit40","first-page":"A510","article-title":"A randomized comparison of once- versus twice-daily MMX\u00ae mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis","volume":"132","author":"Kamm","year":"2007","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gut.2007.138248","article-title":"Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis","volume":"57","author":"Kamm","year":"2008","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0042|cit42","unstructured":"Kamm MA Schreiber S Butler T Barrett K Stephenson D Joseph RE Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of 4-month interim data analysis UEGW Abstract Database 2006 MON G-230"},{"issue":"S1","key":"10.1002\/14651858.CD000544.pub5-BIB0043|cit43","first-page":"S22","article-title":"Ulcerative colitis: patients\u2019 perceptions compared with other chronic diseases","volume":"14","author":"Rubin","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"S1","key":"10.1002\/14651858.CD000544.pub5-BIB0044|cit44","first-page":"S24","article-title":"MMX\u2122 mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis","volume":"14","author":"Sandborn","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"3","key":"10.1002\/14651858.CD000544.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/cgh.2003.50025","article-title":"A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis","volume":"1","author":"Kane","year":"2003","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD000544.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/PPA.S3698","article-title":"Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial","volume":"2","author":"Kane","year":"2008","journal-title":"Patient Preference and Adherence"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD000544.pub5-BIB0047|cit47","first-page":"A220","article-title":"Prophylactic effects of olsalazine (OLZ) versus sulfasalazine (SASP) in 12 months' maintenance treatment of ulcerative colitis","volume":"100","author":"Kiilerich","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/gut.33.2.252","article-title":"Prophylactic effects of olsalazine versus sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Danish Olsalazine Study Group","volume":"33","author":"Kiilerich","year":"1992","journal-title":"Gut"},{"issue":"8","key":"10.1002\/14651858.CD000544.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2036.1998.00360.x","article-title":"Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis","volume":"12","author":"Kruis","year":"1998","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0050|cit50","first-page":"391","article-title":"Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis","volume":"7","author":"Kruis","year":"1995","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0051|cit51","first-page":"A649","article-title":"Double-blind dose-finding study of olsalazine vs. sulfasalazine for maintenance therapy of ulcerative colitis","volume":"102","author":"Kruis","year":"1992","journal-title":"Gastroenterology"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD000544.pub5-BIB0052|cit52","first-page":"A222","article-title":"A double-blind dose finding study of olsalazine for the maintenance treatment of quiescent ulcerative colitis","volume":"100","author":"Kruis","year":"1991","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD000544.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/gut.49.6.783","article-title":"Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses","volume":"49","author":"Kruis","year":"2001","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S768","DOI":"10.1016\/S0016-5085(13)62838-3","article-title":"Optimal dosing of mesalamine for maintenance of clinical remission in patients with distal ulcerative colitis and residual endoscopic activity: a subgroup analysis of a double-blind, double-dummy, randomized, controlled, dose-ranging study","volume":"144","author":"Kruis","year":"2013","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0055|cit55","first-page":"A489","article-title":"Once Daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study","volume":"134","author":"Kruis","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD000544.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2036.2010.04537.x","article-title":"Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis","volume":"33","author":"Kruis","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD000544.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2036.2010.04438.x","article-title":"Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis \u2013 a 6-month placebo-controlled trial","volume":"32","author":"Lichtenstein","year":"2010","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD000544.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2036.2002.01155.x","article-title":"Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis","volume":"16","author":"Mahmud","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0059|cit59","first-page":"A1271","article-title":"Double blind controlled comparison of balsalazide and sulphasalazine in maintenance therapy of patients with ulcerative colitis [abstract]","volume":"27","author":"McIntyre","year":"1986","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2036.1988.tb00693.x","article-title":"Balsalazine in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine","volume":"2","author":"McIntyre","year":"1988","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF02065413","article-title":"Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis","volume":"40","author":"Miner","year":"1995","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0062|cit62","first-page":"A666","article-title":"Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa)","volume":"102","author":"Miner","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0016-5085(88)80061-1","article-title":"Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis","volume":"95","author":"Mulder","year":"1988","journal-title":"Gastroenterology"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD000544.pub5-BIB0064|cit64","first-page":"A313","article-title":"Double blind evaluation of slow-release 5-aminosalicylic acid (Pentasa) and salazopyridin (Salazopyrin) in the maintenance therapy of ulcerative colitis","volume":"94","author":"Mulder","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0065|cit65","first-page":"381","article-title":"Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study","volume":"90","author":"Nilsson","year":"1995","journal-title":"American Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD000544.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2036.2005.02458.x","article-title":"Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study","volume":"21","author":"Paoluzi","year":"2005","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD000544.pub5-BIB0067|cit67","first-page":"A585","article-title":"Doubling daily dosage of oral mesalazine (2.4 vs. 1.2 g) in the maintenance therapy of pts with ulcerative colitis delays but does not reduce incidence of relapses: a 1-year follow-up study","volume":"128","author":"Paoluzi","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/ecco-jcc\/jjx180.644","article-title":"The effects and adherence of Asacol comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: prospective multicentre randomised study","volume":"12","author":"Park","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"3","key":"10.1002\/14651858.CD000544.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5217\/ir.2018.00064","article-title":"Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study","volume":"17","author":"Park","year":"2019","journal-title":"Intestinal Research"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0070|cit70","first-page":"108","article-title":"Randomised open label trial comparing two different dosages of oral mesalazine in the maintenance treatment of ulcerative colitis","volume":"1","author":"Pica","year":"2012","journal-title":"Italian Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0071|cit71","first-page":"390","article-title":"Maintenance treatment of ulcerative colitis with 5-aminosalicylic acid (5-ASA): results from the Italian population of a one year, randomized, multinational study comparing MMx\u00ae with Asacol\u00ae","volume":"136","author":"Kohn","year":"2009","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD000544.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2036.2009.04117.x","article-title":"Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol","volume":"30","author":"Prantera","year":"2009","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0073|cit73","first-page":"438","article-title":"Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: prospective, double-blind, randomized multicenter study","volume":"87","author":"Rijk","year":"1992","journal-title":"American Journal of Gastroenterology"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD000544.pub5-BIB0074|cit74","first-page":"A243","article-title":"The relapse preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission","volume":"100","author":"Rijk","year":"1991","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD000544.pub5-BIB0075|cit75","first-page":"669","article-title":"Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment of patients with ulcerative colitis","volume":"29","author":"Riley","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0016-5085(88)90677-4","article-title":"Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis","volume":"94","author":"Riley","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0077|cit77","first-page":"A1596","article-title":"A comparison of delayed-release 5-ASA and sulfasalazine as maintenance treatment in ulcerative colitis","volume":"92","author":"Riley","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0078|cit78","first-page":"1390","article-title":"A comparison of delayed-release 5-aminosalicylic acid (5-ASA) and sulfasalazine (SSZ) as maintenance treatment of ulcerative colitis (UC)","volume":"28","author":"Riley","year":"1987","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.1989.tb00204.x","article-title":"Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis","volume":"3","author":"Rutgeerts","year":"1989","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD000544.pub5-BIB0080|cit80","first-page":"A1432","article-title":"Azodisal sodium, (ADS), Dipentum, as relapse prevention in ulcerative colitis (UC). A double-blind placebo controlled study","volume":"88","author":"Jarnerot","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/0016-5085(86)90882-6","article-title":"Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse prevention properties","volume":"90","author":"Sandberg-Gertzen","year":"1986","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0082|cit82","first-page":"S15","article-title":"Once daily dosing of delayed-release oral mesalamine for maintenance of remission of ulcerative colitis (the QDIEM trial): 6 and 12 month results","volume":"15","author":"Sandborn","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1002\/14651858.CD000544.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/j.gastro.2009.12.054","article-title":"Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis","volume":"138","author":"Sandborn","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD000544.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/MIB.0000000000001065","article-title":"2.4g Mesalamine (Asacol 400mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial","volume":"23","author":"Suzuki","year":"2017","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/gut.35.9.1282","article-title":"Optimum dose of olsalazine for maintaining remission in ulcerative colitis","volume":"35","author":"Travis","year":"1994","journal-title":"Gut"},{"issue":"8","key":"10.1002\/14651858.CD000544.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1097\/MIB.0b013e318286fa3d","article-title":"Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study","volume":"19","author":"Watanabe","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/BF01296107","article-title":"Olsalazine in maintenance of clinical remission in patients with ulcerative colitis","volume":"38","author":"Wright","year":"1993","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0088|cit88","first-page":"A714","article-title":"Olsalazine in the maintenance of remission in patients with ulcerative colitis","volume":"102","author":"Wright","year":"1992","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD000544.pub5-BIB0089|cit89","first-page":"121","article-title":"5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis","volume":"26","author":"Andreoli","year":"1994","journal-title":"Italian Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0090|cit90","first-page":"334","article-title":"Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis","volume":"26","author":"Bardazzi","year":"1994","journal-title":"Italian Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0091|cit91","first-page":"1143","article-title":"Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study","volume":"92","author":"d'Albasio","year":"1997","journal-title":"American Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD000544.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.14164","article-title":"Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis","volume":"46","author":"D'Haens","year":"2017","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/bmj.285.6347.1012","article-title":"Maintenance of remissions in ulcerative colitis with oral preparation of 5-aminosalicylic acid","volume":"285","author":"Dew","year":"1982","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Dignass A Bokemeyer B Stijnen T Tan T Borner N Oudkerk Pool M Safety of once-daily vs twice-daily mesalazine (Pentasa) dosing. Results from a 12-month randomised controlled trial in maintenance of remission of ulcerative colitis Canadian Journal of Gastroenterology 2009","DOI":"10.1016\/S1873-9946(09)60185-9"},{"issue":"1","key":"10.1002\/14651858.CD000544.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/2050640617703842","article-title":"Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial","volume":"6","author":"Dignass","year":"2018","journal-title":"United European Gastroenterology Journal"},{"issue":"1","key":"10.1002\/14651858.CD000544.pub5-BIB0096|cit96","first-page":"47","article-title":"Comparable efficacy of oral 5-ASA (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission","volume":"26","author":"Eliakim","year":"1990","journal-title":"Israel Journal of Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD000544.pub5-BIB0097|cit97","first-page":"225","article-title":"Systemic uptake of 5-aminosalicylic acid from olsalazine and Eudragit L coated mesalazine in patients with ulcerative colitis in remission","volume":"34","author":"Ewe","year":"1996","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"2","key":"10.1002\/14651858.CD000544.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1572-0241.1999.872_a.x","article-title":"Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis","volume":"94","author":"Fern\u00e1ndez-Ba\u00f1ares","year":"1999","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000544.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.dld.2004.09.017","article-title":"Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis","volume":"37","author":"Frieri","year":"2005","journal-title":"Digestive and Liver Disease"},{"issue":"1","key":"10.1002\/14651858.CD000544.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2036.1992.tb00544.x","article-title":"Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine","volume":"6","author":"Giaffer","year":"1992","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD000544.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.MIB.0000437500.60546.2a","article-title":"Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis","volume":"20","author":"Gillespie","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0016-5085(90)91334-3","article-title":"Pentasa in maintenance treatment of ulcerative colitis","volume":"98","author":"Gionchetti","year":"1990","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD000544.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1365-2036.1996.26168000.x","article-title":"Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation","volume":"10","author":"Gionchetti","year":"1996","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD000544.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2036.2004.01866.x","article-title":"Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study","volume":"19","author":"Green","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0105|cit105","first-page":"494","article-title":"MMX mesalamine for induction and maintenance therapy in mild-to-moderate ulcerative colitis","volume":"5","author":"Hanauer","year":"2009","journal-title":"Gastroenterology and Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD000544.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/00042737-199611000-00010","article-title":"Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine","volume":"8","author":"Karamanolis","year":"1996","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD000544.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1046\/j.1365-2036.1997.00225.x","article-title":"Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis","volume":"11","author":"Kruis","year":"1997","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD000544.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.1093\/ecco-jcc\/jjx002.534","article-title":"Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study","volume":"11","author":"Levine","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0110|cit110","first-page":"49","article-title":"Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral Mesalamine: a prospective cohort study","volume":"64","author":"Levine","year":"2017","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000544.pub5-BIB0111|cit111","first-page":"A124","article-title":"Comparison of pharmacokinetics and colonic transit time in quiescent ulcerative colitis on mesalazine and olsalazine \u2013 a cross over study","volume":"35","author":"Mani","year":"1994","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD000544.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1572-0241.2004.11481.x","article-title":"A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis","volume":"99","author":"Mantzaris","year":"2004","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD000544.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00004836-199706000-00026","article-title":"5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis","volume":"24","author":"Odes","year":"1997","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD000544.pub5-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S0016-5085(14)60529-1","article-title":"A randomized controlled trial of mesalamine dose escalation for ulcerative colitis in remission","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD000544.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1590-8658(02)80072-X","article-title":"Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial","volume":"34","author":"Paoluzi","year":"2002","journal-title":"Digestive and Liver Disease"},{"issue":"Suppl 2 Pt 2","key":"10.1002\/14651858.CD000544.pub5-BIB0116|cit116","first-page":"A54","article-title":"Systematic load of 5-ASA in patients with inactive ulcerative colitis treated with olsalazine and mesalazine","volume":"37","author":"Papatheodoridis","year":"1995","journal-title":"Gut"},{"issue":"10","key":"10.1002\/14651858.CD000544.pub5-BIB0117|cit117","first-page":"556","article-title":"Comparison of Mutaflor and mesalazine in the maintenance treatment of inactive ulcerative colitis","volume":"78","author":"Pelech","year":"1998","journal-title":"Prakticky Lekar"},{"issue":"11","key":"10.1002\/14651858.CD000544.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.dld.2015.07.011","article-title":"A randomized trial comparing 4.8 vs. 2.4 g\/day of oral mesalazine for maintenance of remission in ulcerative colitis","volume":"47","author":"Pica","year":"2015","journal-title":"Digestive & Liver Disease"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/ecco-jcc\/jjx032","article-title":"Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: a randomised, placebo-controlled trial","volume":"11","author":"Rubin","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.14309\/00000434-201310001-01807","article-title":"Long-term safety and tolerability of twice-daily balsalazide disodium tablets in patients with ulcerative colitis","volume":"108","author":"Scherl","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/gut.31.11.1271","article-title":"Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion","volume":"31","author":"Staerk Laursen","year":"1990","journal-title":"Gut"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000544.pub5-BIB0122|cit122","first-page":"A121","article-title":"The systemic load and efficient delivery of active 5-ASA in patients with ulcerative colitis on treatment with Dipentum (olsalazine) and Mesasael (mesalazine)","volume":"35","author":"Florholmen","year":"1994","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2036.1999.00483.x","article-title":"The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine","volume":"13","author":"Stoa-Birketvedt","year":"1999","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD000544.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12325-016-0304-y","article-title":"Mesalazine modified-release tablet in the treatment of ulcerative colitis in the remission phase: a Chinese, multicenter, single-blind, randomized controlled study","volume":"33","author":"Sun","year":"2016","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0125|cit125","first-page":"A1030","article-title":"Oral 5-aminosalicylic acid therapy for the prevention of relapse in patients with ulcerative colitis (UC) during remission: a new therapeutical approach by using 5-ASA tablets 800 mg. A multicenter controlled randomized trial","volume":"110","author":"Tragnone","year":"1996","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD000544.pub5-BIB0126|cit126","first-page":"527","article-title":"Once- versus twice-daily mesalazine to induce remission in paediatric ulcerative colitis: a randomised controlled trial","volume":"11","author":"Turner","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD000544.pub5-BIB0127|cit127","first-page":"A75","article-title":"Disposition of 5-ASA by olsalazine (Dipentum) and mesalazine (Asacol) in patients with ulcerative colitis in remission","volume":"39","author":"Archimandritis","year":"1996","journal-title":"Gut"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00042737-199707000-00016","article-title":"Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine","volume":"9","author":"Tzivras","year":"1997","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD000544.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/ibd.20158","article-title":"Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study","volume":"13","author":"Yokoyama","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1365-2036.2006.02927.x","article-title":"Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis","volume":"23","author":"Zocco","year":"2006","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0131|cit131","unstructured":"Phosphatidylcholine (LT-02) vs. placebo vs. mesalamine for maintenance of remission in ulcerative colitis (PROTECT-2) clinicaltrials.gov\/show\/NCT02280629"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0132|cit132","unstructured":"Mesalamine 2 g Sachet for the maintenance of clinical and endoscopic remission in ulcerative colitis (UC) clinicaltrials.gov\/show\/NCT02522780"},{"issue":"17","key":"10.1002\/14651858.CD000544.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJM199504273321703","article-title":"Discontinuation of antihyperlipidemic drugs \u2013 do rates reported in clinical trials reflect rates in primary care settings?","volume":"332","author":"Andrade","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"8044","key":"10.1002\/14651858.CD000544.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulfasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0135|cit135","unstructured":"Beaulieu DB Schwartz DA Medication persistence in patients with ulcerative colitis: meeting the challenges and improving patient outcomes CME MedScape CME Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0136|cit136","doi-asserted-by":"crossref","unstructured":"Brixner D Magowan S Accortt N Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers Academy of Managed Care Pharmacy 19th Annual Meeting; 2007 Apr 10\u201313; San Diego (CA), 2007","DOI":"10.1097\/00054725-200705005-00086"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/BF01299921","article-title":"Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide","volume":"28","author":"Chan","year":"1983","journal-title":"Digestive Diseases and Sciences"},{"issue":"18","key":"10.1002\/14651858.CD000544.pub5-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM197309062891001","article-title":"Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype","volume":"289","author":"Das","year":"1973","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2125.1982.tb01999.x","article-title":"An oral preparation to release drugs in the human colon","volume":"14","author":"Dew","year":"1982","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1572-0241.2007.01212.x","article-title":"Predictors of medication adherence in inflammatory bowel disease","volume":"102","author":"Ediger","year":"2007","journal-title":"American Journal of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD000544.pub5-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.mayocp.2014.07.002","article-title":"Ulcerative colitis","volume":"89","author":"Feuerstein","year":"2014","journal-title":"Mayo Clinic Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD000544.pub5-BIB0143|cit143","first-page":"173","article-title":"Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis","volume":"40","author":"Fleig","year":"1988","journal-title":"Digestion"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/ajg.2011.296","article-title":"Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2036.1993.tb00110.x","article-title":"Review article: the mode of action of the aminosalicylates in inflammatory bowel disease","volume":"7","author":"Greenfield","year":"1993","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"7650","key":"10.1002\/14651858.CD000544.pub5-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2036.1987.tb00627.x","article-title":"Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease","volume":"1","author":"Hardy","year":"1987","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0150|cit150","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0151|cit151","unstructured":"Higgins JP Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"Suppl 148","key":"10.1002\/14651858.CD000544.pub5-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365528809101561","article-title":"Olsalazine in patients intolerant of sulfasalazine","volume":"23","author":"Ireland","year":"1988","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0153|cit153","first-page":"A932","article-title":"Withdrawal rates because of diarrhoea in Dipentum-treated patients with ulcerative colitis are low when Dipentum is taken with food and dose titrated [abstract]","volume":"110","author":"Jarnerot","year":"1996","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD000544.pub5-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.2001.04683.x","article-title":"Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis","volume":"96","author":"Kane","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD000544.pub5-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9343(02)01383-9","article-title":"Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis","volume":"114","author":"Kane","year":"2003","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD000544.pub5-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2036.2006.02809.x","article-title":"Systematic review: adherence issues in the treatment of ulcerative colitis","volume":"23","author":"Kane","year":"2006","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1 Suppl A","key":"10.1002\/14651858.CD000544.pub5-BIB0157|cit157","first-page":"S2","article-title":"The challenge of compliance and persistence: focus on ulcerative colitis","volume":"14","author":"Kane","year":"2008","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/00365528909089231","article-title":"Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis","volume":"24","author":"Kjaergaard","year":"1989","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198012253032602","article-title":"Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease","volume":"303","author":"Klotz","year":"1980","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD000544.pub5-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1111\/j.1572-0241.1999.01200.x","article-title":"Increasing patient adherence to gastroenterology treatment and prevention regimens","volume":"94","author":"Levy","year":"1999","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD000544.pub5-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.14309\/00000434-200609001-01144","article-title":"5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens","volume":"101","author":"Magowan","year":"2006","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(65)90972-4","article-title":"Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis","volume":"1","author":"Misiewitz","year":"1965","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.28.2.196","article-title":"Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract","volume":"28","author":"Myers","year":"1987","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00365528209182073","article-title":"Sulfasalazine intolerance: a retrospective study of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease","volume":"17","author":"Nielsen","year":"1982","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2125.1983.tb02254.x","article-title":"Kinetics of 5-aminosalicylic acid after jejunal instillation in man","volume":"16","author":"Nielsen","year":"1983","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0022-3565(25)29238-2","article-title":"The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine","volume":"181","author":"Peppercorn","year":"1972","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/00365528709078600","article-title":"Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulfasalazine","volume":"22","author":"Rao","year":"1987","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0016-5085(82)80075-9","article-title":"5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans","volume":"83","author":"Rasmussen","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0170|cit170","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/gut.28.8.1008","article-title":"Sulfasalazine induced seminal abnormalities in ulcerative colitis: result of mesalazine substitution","volume":"28","author":"Riley","year":"1987","journal-title":"Gut"},{"issue":"30","key":"10.1002\/14651858.CD000544.pub5-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.3748\/wjg.v12.i30.4819","article-title":"Extraintestinal manifestations and complications in inflammatory bowel diseases","volume":"12","author":"Rothfuss","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD000544.pub5-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/j.1572-0241.2002.07092.x","article-title":"Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis","volume":"97","author":"Sandborn","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0002-9270(02)05284-X","article-title":"Comparable systemic absorption of 5-ASA and N-AC-5-ASA from U.S. Asacol and Colazal","volume":"97","author":"Sandborn","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/S0002-9270(02)05301-7","article-title":"The pharmacokinetic profiles of oral 5ASA formulations used in the management of ulcerative colitis: a systematic review","volume":"97","author":"Sandborn","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD000544.pub5-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/cpt1972134539","article-title":"Absorption, metabolism, and excretion of salicylazosulfapyridine in man","volume":"13","author":"Schroeder","year":"1972","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0178|cit178","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD000544.pub5-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1365-2036.2003.01648.x","article-title":"Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease","volume":"18","author":"Shale","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.0954-6820.1942.tb06841.x","article-title":"Salazopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation","volume":"110","author":"Svartz","year":"1942","journal-title":"Acta Medica Scandinavica"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis: final report on a therapeutic trial","volume":"4947","author":"Truelove","year":"1955","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/bmj.1.5119.387","article-title":"Cortisone and corticotrophin in ulcerative colitis","volume":"i","author":"Truelove","year":"1959","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gut.21.7.632","article-title":"Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulfasalazine","volume":"21","author":"Van Hees","year":"1980","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.23.12.1081","article-title":"Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis","volume":"23","author":"Willoughby","year":"1982","journal-title":"Gut"},{"issue":"10","key":"10.1002\/14651858.CD000544.pub5-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000544.pub3","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Feagan","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/0003-4819-118-7-199304010-00009","article-title":"Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis","volume":"118","author":"Sutherland","year":"1993","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD000544.pub5-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00054725-199706000-00001","article-title":"Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis","volume":"3","author":"Sutherland","year":"1997","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"10.1002\/14651858.CD000544.pub5-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000544.pub2","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Sutherland","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD000544.pub5-BIB0189|cit189","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000544.pub4","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Wang","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:38:14Z","timestamp":1788500294000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000544.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Gut Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":189,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000544.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]}}}